Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Protecting Seniors Access to Medicare Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Importation - Affordable and Safe Prescription Drug Importation Act- Sanders
Source: Senate LDA
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
American Family Act of 2017
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Affordable and Safe Prescription Drug Importation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
A concurrent resolution setting forth the congressional budget for the United States Government for fiscal year 2017 and setting forth the appropriate budgetary levels for fiscal years 2018 through 2026.
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S.1200 (Fairness to Pet Owners Act).
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S.1200
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S.1200 (Fairness to Pet Owners Act).
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Veterinary Biologics, S.1200
Medicare Access and CHIP Reauthorization Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Confidential Informant Accountability Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Quarterly Financial Report Reauthorization Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Innovation Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
PATENT Act
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding of Animal Drugs; Veterinary Biologics, S.1200 - Fairness to Pet Owners Act
Fairness to Pet Owners Act of 2015
Client: BOEHRINGER INGELHEIM USA CORPORATION · Firm: BOEHRINGER INGELHEIM USA CORPORATION, FORMERLY REPORTED AS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC
Illegal Compounding of Animal Drugs; Vetex Veterinary Biologics, S.1200 - Fairness to Pet Owners Act
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Con. Res. 3 - 2017 Budget President's 2018 Budget Blue Print
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Average Sales Price; Reimbursement; 21st Century Cures. CMS Rule Blended J Code for Biosimilars; IPAB (Independent Payment Advisory Board).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Non-Interference; and Drug Pricing. HR. 849 Protecting Seniors' Access to Medicare Act of 2017 (IPAB) Medicare S. Cong. Reg. 3 - 2017 Budget President's 2018 Budget Blue Print
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Transparency - Fair Drug Pricing Act - Baldwin/McCain.
Cost Sharing (Preserving Access to Medicines); S. Amendment 178; to S. Con. Res. 3 and HR/245 & S.469 House & Senate bills titled the Affordable Safe and Prescription Drug Importation Act
Veterinary Biologics, S. 1200 (Fairness to Pet Owners Act).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines).
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Prescription Drug User Fee Act VI reauthorization; 21st Century Cures Proposal.
Veterinary Biologics, S.1200 (Fairness to Pet Owners Act).
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal and Transparency.
Veterinary Biologics, S.1200 (Fairness to Pet Owners Act).
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Cost Sharing (Preserving Access to Medicines).
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Veterinary Biologics, S.1200
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Veterinary Biologics, S.1200
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Average Sales Price; Reimbursement; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Illegal Compounding of Animal Drugs; Vetex Veterinary Biologics, S.1200 - Fairness to Pet Owners Act
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 2985 Combined Drug Development Incentive Act; HR 3116 Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S-1137 Patent Act.
Average Sales Price; Reimbursement; Medicare Sustainable Growth Rate Bill HR 2 and Children Health Insurance Program Act of 2015; 21st Century Cures.
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; 21st Century Cures Proposal.
Average Sales Price; Reimbursement; 21st Century Cures. CMS Part B Centers for Medicare and Medicaid Innovation Demonstration (CMMI); CMS Rule Blended J Code for Biosimilars.
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non-Interference; and Drug Pricing.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Illegal Compounding of Animal Drugs; Veterinary Biologics, S.1200 - Fairness to Pet Owners Act
Food and Drug Administration Safety & Innovation Act (FDASIA) [Implementation]; Prescription Drug User Fee Act VI; 21st Century Cures Proposal.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Average Sales Price; Reimbursement; Children Health Insurance Program Act of 2015; 21st Century Cures.
Cost Sharing (Preserving Access to Medicines); HR 9 - Patent Bill; Healthcare Exchanges; HR 3116 - Modernizing our Drug & Diagnostic Evaluation & Regulatory Network; S.1137 - Patent Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
House & Senate Budget Bills; Rebates for Dual Eligible and Low Income Subsidy Populations in Medicare Part D; Importation; Non Interference.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE